[ad_1]
The United States-based drug regulator, the United States Food & Drug Administration (USFDA), has concluded a remote review of the records of Unit III of Shilpa Medicare, an R&D facility located in Dabaspet, Bengaluru, without any objectionable conditions or observations.
The review was conducted from Monday, November 15, 2021 to Thursday, November 18, 2021. The Research and Development (R&D) Unit III of Shilpa Medicare in Dabaspet, Bengaluru (Karnataka) is involved in the development of formulations (generic, generic complex and innovative products) and provide advanced analytical services.
On a consolidated basis, Shilpa Medicare net profit fell 56% to Rs 19.89 crore on a 5.9% increase in net sales to Rs 295.27 crore in the second quarter of September 2021 compared to the second quarter September 2020.
Shilpa Medicare is a global brand of manufacturing and supplying affordable APIs and formulations globally in various regulated markets.
Shilpa Medicare shares fell 0.70% to close at Rs 560.75 on Thursday, November 18, 2021. The national stock market is closed today, November 19, 2021 because of Guru Nanak Jayanti.
Powered by Capital Market – Live News
(This story was not edited by Business Standard staff and is auto-generated from a syndicated feed.)
Dear reader,
Business Standard has always strived to provide up-to-date information and commentary on developments that matter to you and have broader political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering has only strengthened our resolve and commitment to these ideals. Even in these difficult times resulting from Covid-19, we remain committed to keeping you informed and updated with credible news, authoritative views and cutting edge commentary on relevant current issues.
However, we have a demand.
As we fight the economic impact of the pandemic, we need your support even more so that we can continue to provide you with more quality content. Our subscription model has received an encouraging response from many of you who have subscribed to our online content. More subscriptions to our online content can only help us achieve the goals of providing you with even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practice the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital editor
[ad_2]
